Glucagon-like peptide-1 receptor agonists (GLP-1RA) are used in obesity management because they induce weight loss via appetite inhibition.14,15,16 Physical activity is recommended for healthy weight loss, but most evidence is from prospective cohort studies.17 Exercise decreases fat mass and preserves or increases lean mass.18 In a recent trial,19 1 year of treatment with the GLP-1RA liraglutide (3.0 mg) or exercise as separate treatments maintained diet-induced weight loss and improved body composition. Here, GLP1R is linked to obesity due to melanocortin 4 receptor deficiency.